𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Treatment of small cell carcinoma of the lung with copp

✍ Scribed by Nixon, Daniel W.


Publisher
John Wiley and Sons
Year
1984
Tongue
English
Weight
282 KB
Volume
12
Category
Article
ISSN
0098-1532

No coin nor oath required. For personal study only.

✦ Synopsis


The COPP regimen (cyclophosphamide, Oncovin, procarbazine, prednisone) was one of the first chemotherapy programs to prolong survival in small cell lung cancer (SCLC) significantly. Results with this regimen in 50 patients with SCLC show an overall median survival of 10 months. Survival was decreased with more extensive disease. Patients given COPP plus irradiation to the primary lesion lived longer than those given COPP alone, but this difference was not statistically significant. Toxicity was relatively mild. The COPP regimen can be considered, especially in advanced SCLC, if coexisting cardiac or renal disease precludes the use of agents toxic to these organs.


πŸ“œ SIMILAR VOLUMES


Treatment of small cell lung carcinoma i
✍ Esther Dajczman; Li Yi Fu; David Small; Norman Wolkove; Harvey Kreisman πŸ“‚ Article πŸ“… 1996 πŸ› John Wiley and Sons 🌐 English βš– 625 KB

## BACKGROUND. The number of elderly people with small cell lung carcinoma (SCLC) is increasing and currently nearly 25% are older than 70 years. Elderly patients may not tolerate intensive therapy and, therefore, often do not receive such treatment. Additionally, age may be an independent predicto

Systemic scleroderma and small cell carc
✍ Deba P. Sarma; Thomas G. Weilbaecher πŸ“‚ Article πŸ“… 1985 πŸ› John Wiley and Sons 🌐 English βš– 266 KB

## Abstract A 64‐year‐old man diagnosed to have systemic scleroderma for 1 year developed small‐cell carcinoma of the lung. Six additional cases obtained from the literature describing small‐cell carcinoma occurring in patients with scleroderma are reviewed.